- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | VENUS MEDTECH-B (02500): PROXY FORM FOR USE AT THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| Mi | VENUS MEDTECH-B (02500): NOTICE OF 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| VENUS MEDTECH Aktie jetzt für 0€ handeln | |||||
| Mi | VENUS MEDTECH-B (02500): (1) 2025 ANNUAL REPORT (2) WORK REPORT OF THE BOARD FOR 2025 (3) WORK REPORT OF THE SUPERVISORY COMMITTEE FOR 2025 (4) PROFIT ... | 3 | HKEx | ||
| 26.05. | Venus Medtech Hosts Inaugural Global Partner Summit in Paris | 388 | PR Newswire | Company highlights international growth strategy, expanding structural heart portfolio, and commercialization prioritiesPARIS, May 26, 2026 /PRNewswire/ -- Venus Medtech convened its inaugural... ► Artikel lesen | |
| 19.05. | VENUS MEDTECH-B (02500): EXCHANGE'S DISCIPLINARY ACTION AGAINST FORMER COMPANY SECRETARY OF VENUS MEDTECH (HANGZHOU) INC. (STOCK CODE: 2500) | 1 | HKEx | ||
| 15.05. | VENUS MEDTECH-B (02500): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 15.05. | VENUS MEDTECH-B (02500): RESIGNATION OF A DIRECTOR | - | HKEx | ||
| 06.05. | VENUS MEDTECH-B (02500): CHANGE OF COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVES | - | HKEx | ||
| 29.04. | VENUS MEDTECH-B (02500): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | VENUS MEDTECH-B (02500): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 31.03. | VENUS MEDTECH-B (02500): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 19.03. | VENUS MEDTECH-B (02500): DATE OF BOARD MEETING | 3 | HKEx | ||
| 22.01. | VENUS MEDTECH-B (02500): FURTHER ANNOUNCEMENT IN RELATION TO THE PATENT INFRINGEMENT LAWSUIT | 1 | HKEx | ||
| 20.01. | VENUS MEDTECH-B (02500): ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES | 1 | HKEx | ||
| 29.12.25 | VENUS MEDTECH-B (02500): DISCLOSEABLE TRANSACTION IN RELATION TO DISPOSAL OF SHARES OF AN INVESTEE COMPANY | 1 | HKEx | ||
| 24.12.25 | VENUS MEDTECH-B (02500): VOLUNTARY ANNOUNCEMENT SUBMISSION OF CE MDR MARKING APPLICATION FOR THE CARDIOVALVE TRICUSPID VALVE REPLACEMENT | 2 | HKEx | ||
| 17.11.25 | Venus Medtech (Hangzhou) Inc.: Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion | 524 | PR Newswire | Exciting Data on Cardiovalve Tricuspid Valve Replacement Device Presented at PCR London Valves 2025 meeting.
LONDON, Nov. 17, 2025 /PRNewswire/ -- Venus Medtech... ► Artikel lesen | |
| 25.10.25 | Venus Medtech (Hangzhou) Inc.: Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement | 734 | PR Newswire | The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch
HANGZHOU, China, Oct. 25, 2025 /PRNewswire/... ► Artikel lesen | |
| 05.08.25 | Venus Medtech (Hangzhou) Inc.: Court Sides with Cardiovalve in Edwards patent spat | 332 | PR Newswire | HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 35,960 | -1,34 % | Während Merck, Amgen, Novo Nordisk und Fresenius Milliarden bewegen, wächst die Fantasie im Zelltherapie-Sektor | ||
| SIEMENS HEALTHINEERS | 33,500 | -1,59 % | Mentice AB: Mentice and Siemens Healthineers Announce Co-Marketing Partnership to Advance Neurovascular Treatment Planning | Gothenburg, Sweden - June 2026 - Mentice AB, a global leader in simulation and clinical decision support solutions for Image-Guided Therapies, today announced a co-marketing agreement with Siemens Healthineers... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 36,020 | +0,92 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung gemäß Artikel 5 Abs. 1 lit. a) der Verordnung (EU) Nr. 596/2014 und Artikel 2 Abs. 1 der Delegierten... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 14,270 | +0,14 % | Alignment Healthcare Named to the Fortune 1000 2026 List for Second Consecutive Year | ||
| BRIGHTSPRING HEALTH SERVICES | 60,87 | -0,02 % | BrightSpring stockholders to sell 15M shares in offering | ||
| AVEANNA HEALTHCARE | 6,780 | 0,00 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Completes Acquisition of Family First Homecare and Updates Full Year 2026 Guidance | ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient... ► Artikel lesen | |
| GENEDX | 53,06 | +0,07 % | Sema4.ai's autonomous agent building platform gets simpler to use, adds deeper business context and more | ||
| BILLIONTOONE | 98,21 | -0,15 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| ALPHA TAU MEDICAL | 10,585 | +0,05 % | Alpha Tau Medical Ltd.: Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting | - Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of... ► Artikel lesen | |
| PROGYNY | 25,010 | +0,08 % | Progyny, Inc.: New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System | ||
| HEARTFLOW | 28,870 | +0,07 % | Heartflow, Inc.: Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 26,240 | +0,54 % | EQS-DD: Carl Zeiss Meditec AG: Peter Kameritsch, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
28.05.2026 / 14:57... ► Artikel lesen | |
| ANTERIS TECHNOLOGIES GLOBAL | 8,950 | 0,00 % | ANTERIS TECHNOLOGIES GLOBAL CORP.: Notification of cessation of securities - AVR | ||
| GERRESHEIMER | 26,300 | +0,69 % | Aktien - Shortseller-Positionen: Delivery Hero, Gerresheimer, GFT, Hensoldt, Nagarro, Redcare, Renk, RTL | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| ADAPTHEALTH | 9,740 | +0,21 % | AdaptHealth Corp. - 10-Q, Quarterly Report |
Das Unternehmen VENUS MEDTECH HANGZHOU INC kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VENUS MEDTECH HANGZHOU INC finden Sie auf Wallstreet Online.